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1. Introduction
  Hepatitis E virus (HEV), a member of the genus Hepevirus 
in the family Hepeviridae is a small RNA virus[1]. HEV 
infection occurs in mammals, including humans, domestic 
pigs, wild boar, deer and rodents. HEV has been classified 
into four major genotypes by molecular characterization and 
HEV genotype 3 has been identified almost worldwide[2]. 
HEV is an emerging pathogen worldwide including Asia 
and the Far East[4]. In Thailand, seroprevalence of HEV 
ranges from 9% to 22% in adult subjects and increases with 
age[4]. This prevalence is comparable with the data from 
east Asia[5]. In occupational risk groups such as pig and 
poultry farmers who have worked in farms for more than 2 
years, HEV prevalence amounted to 27.9%[6]. HEV has been 
known to be transmitted via contaminated water in endemic 
areas and recent data have demonstrated animal to human 
transmission in almost every part of the world[7-9].
  In developed countries, hepatitis E infection is more 
common than previously recognized and might be more 
common than hepatitis A[10]. The majority of patients 
with acute HEV infection remain asymptomatic[11]. 
Objective: To report clinical outcomes and viral genotypes of acute symptomatic hepatitis E virus 
(HEV) infection in Thailand. Methods: Forty patients with acute symptomatic HEV infection were 
recruited during 2009-2013. Clinical, demographic and laboratory data were collected. Diagnosis 
was accomplished by detection of anti-HEV IgM and/or HEV RNA in the serum or stool. HEV 
genotypes were classified by direct sequencing of RT-PCR products and phylogenetic analysis. 
Results: The high risk group, comprising immune-compromised, liver cirrhosis and very elderly 
(>80 years) patients (17 cases), had higher levels of serum alkaline phosphatase at presentation 
compared with the low risk group. Two fatal cases resulted from acute hepatitis E in the high risk 
group. Initial clinical presentation did not show statistically significant differences. In six cases 
(6/40), the virus could be detected in serum or stool by RT-PCR and sequencing. Upon molecular 
characterization, the viruses were classified as HEV genotype 3f and were in the same cluster as 
Thai swine HEV. Conclusions: Our data showed that acute HEV infection has various clinical 
presentations and outcomes. Higher levels of serum alkaline phosphatase were observed in high 
risk patients. All isolated viruses were identified as HEV genotype 3f possibly originating from 
swine.
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Clinical manifestations of acute hepatitis E can range from 
asymptomatic to fulminant with ensuing liver failure[12]. 
The risk of acute or subacute liver failure from acute 
HEV infection is exacerbated by pre-existing chronic 
liver disease[13]. In case of liver cirrhosis, HEV infection 
can induce rapid liver decompensation and death[14]. In 
contrast to generally healthy individuals, HEV infection can 
become chronic in post organ transplant patients[15]. Extra-
hepatic presentations, for example, as previously reported 
neurological symptoms such as aseptic meningitis and 
neuralgic amyotrophy are unusual[16].
  Acute HEV infection can be detected by laboratory tests for 
anti-HEV IgM with sensitivities and specificities of close to 
90% and 100%, respectively[17]. False positives of anti-HEV 
IgM can appear in some conditions including acute hepatitis 
A[18]. Molecular techniques appear to be complementary for 
diagnosing HEV infection during early acute infection and 
in immunosuppressed patients[19].
  Clinical data, outcomes and risk factors of patients 
with acute HEV infection in Thailand have not been well 
researched. Our study has aimed at reporting clinical 
outcomes, distribution of disease and genotypes of acute 
symptomatic HEV infection in Thailand.
2. Materials and methods
  
  This study was conducted on acute HEV patients who 
presented at or were referred to King Chulalongkorn 
Memorial Hospital during 2009 to 2013. The research 
protocol was approved by the Institutional Review Board, 
Faculty of Medicine, Chulalongkorn University. 
2.1. Patients
   Forty patients with acute symptomatic HEV infection, 
who attended or were hospitalized at King Chulalongkorn 
Memorial Hospital during 2009-2013 were recruited. Acute 
HEV infection was diagnosed when the clinical presentation 
was consistent with acute hepatitis and serum was positive 
for HEV-IgM. All patients were assessed for other viral 
hepatitis and chronic liver diseases. Clinical, demographic 
and laboratory data were collected from the hospital records. 
Patients were divided into high and low risk groups. The 
high risk group comprised very elderly patients (>80 years), 
liver cirrhosis patients or patients who were immune-
compromised due to previous organ transplantation, 
chemotherapy or HIV infection. None of these risk factors 
applied to patients in the low risk group. This study did not 
include acute HEV infection during pregnancy. A case of 
HEV infection with neurological complications has been 
reported elsewhere[16]. 
 2.2. Clinical assessment
  Initial demographic data, clinical presentation and 
laboratory data were obtained. Duration of hospitalization 
and clinical outcome were analyzed. 
2.3. Laboratory methods
   Enzyme linked immunosorbent assay (ELISA) was used to 
determine anti-HEV IgM antibodies (DIA.PRO Diagnostic 
Bioprobes Srl, Sesto San Giovammi, Milano, Italy) according 
to the manufacturer’s specifications. 
2.4. HEV-RNA detection and genotyping
     
  The serum and/or stool samples obtained in this study 
were tested for HEV-RNA by one step-semi-nested reverse 
transcription polymerase chain reaction (RT-PCR). Briefly, 
the cDNA was amplified by nested PCR using three primers 
comprising an inner sense forward primer HE5-1 (nt 19-
37) 5’-TCG ATG CCA TGG AGG CCC A-3’, and two outer 
antisense primers HE5-4 (nt 541-60) 5’-CAT AGC CTC SGC 
RAC ATC AG-3’and HE5-5 (nt 541-560) 5’-CAT YGC CTC 
SGC AAC ATC GG-3’ for the first round of PCR amplification 
and HE5-2 (nt 105-123) 5’-GCC YTK GCG AAT GCT GTG 
G-3’, HE5-3 (nt 450-469) 5’-TCR AAR CAG TAR GTG CGG 
TC-3’ and HE5-6 (nt450-469) 5’-TYA AAA CAG TAG GTT 
CGA TC-3’ for the second round. Each reaction mixture 
comprised 1.5 毺L and 0.5 毺L of template for the primary 
and secondary PCR, respectively, combined with 10.0 毺L 
of 2.5× Master Mix (Perfect Taq Plus, Hamburg, Germany), 
five primers with each primer at a final concentration of 
0.5 毺mol/L, and nuclease free water to a final volume of 
25.0 毺L. Both amplification reactions were carried out in a 
Mastercycler Personal (Eppendorf, Hamburg, Germany). After 
an initial denaturation step at 95 曟 for 3 min, amplification 
was performed for 35 cycles including denaturation (94 曟 for 
45 s), annealing (50 曟 for 45 s) and extension (72 曟 for 78 s), 
followed by a final extension step at 72 曟 for 10 min. A total 
of 25 毺L of amplified product was subjected to 2% agarose 
gel (Agarose molecular grade; Promega, WI) electrophoresis 
at 100 V for 1 h and then stained with ethidium bromide. The 
expected amplified product (approximately 365 bp in length) 
was visualized on a UV transilluminator (Gel Doc 1000, BIO-
RAD, CA). 
2.5. HEV sequencing
  The cDNA of all samples were amplified by semi-nested 
PCR with the above primers to determine subtype. The band 
of interest was excised and purified using the GelElute 
Extraction kit (5 prime, Hamburg, Germany) according 
to the manufacturer’s specifications for whole genome 
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sequencing. The purified DNA served as templates for DNA 
sequencing performed by FirstBASE Laboratories SDNBHD 
(Selangor Darul Ehsan, Malaysia). The nucleotide sequences 
were analyzed in both directions using forward and reverse 
primers to confirm the consistency of the sequencing result 
and ensure that variations of nucleotide sequences were 
not due to sequencing errors. The genotype was determined 
by BLAST/FASTA (http://www.ncbi.nlm.nih.gov) analysis. 
The sequences were edited and assembled by using 
programs CHROMAS LITE v.2.0 (www.technelysium.com.
au) and SeqMan (DNASTAR, Madison, WI). Multiple protein 
translation and sequence alignments were generated with 
BioEdit version 7.0.1 (http://www.mbio.ncsu.edu/BioEdit/
bioedit.html).
2.6. Phylogenetic analysis of HEV 
  All sequences were multiple aligned using Clustal X 
Version 1.8 and the nucleotide identities with reference 
sequences were analyzed using the BioEdit Sequence 
Alignment Editor version 5.0.9. Phylogenetic trees were 
constructed using the Neighbor-Joining Method of the 
MEGA (Molecular Evolutionary Genetics Analysis) version 
3.1 software. To investigate the relationship between HEV 
strains, an un-rooted tree topology based on multiple 
alignments of the ORF1 and ORF2 nucleotide sequences and 
those of known genotypes from Genbank (genotypes 1, 2, 3a, 
3b, 3c, 3d, 3e, 3f and 4) was established by the neighbor-
joining method, and calculation was done with MEGA 3.1 
(http://www.megasoftware.net). Consistency of branching 
was tested by bootstrap analysis with 1 000 re-samplings of 
the data using MEGA 3.1. Multiple protein translation and 
sequence alignments were generated with BioEdit version 
7.0.1 (http://www.mbio.ncsu.edu/BioEdit/bioedit.html).
2.7. Statistical analysis
  Continuous variables were compared between groups using 
unpaired t-test  and one-way ANOVA. Categorical variables 
were compared between groups using chi-square/Fisher’s 
exact test. All statistical analyses were performed using SPSS 
version 16.
3. Results
  From 2009 to 2013, 40 patients were diagnosed with acute 
HEV infection. They comprised 32 males and 8 females, and 
their age ranged from 27 to 92 years with a median age of 
49 years. Seven patients were immune-compromised. Five 
very elderly patients were above the age of 80 years and five 
patients had liver cirrhosis. Eight cases (20%) have a history 
of exposure to raw pork (Table 1). Residence and region 
of exposure of acute HEV cases were in various regions of 
Thailand (Figure 1). In this study, 16 of 40 patients were 
classified as high risk group. Clinical presentations were 
not statistically different between the high risk and low 
risk group(Table 2). Laboratory data were not statistically 
different between the high risk and low risk group except for 
higher levels of serum alkaline phosphatase at presentation 
in the high risk group, (221±119) vs. (156±57) U/L, P=0.01) 
(Table 3). Mean duration of hospitalization was longer in 
the high risk group than the low risk group (31.8 vs. 10.6 d, 
P=0.13).
Figure 1. Regions of exposure (red) and residence (yellow) of acute 
HEV cases in Thailand. 
Regions of confirmed relevant exposure included Nonthaburi, 
Ubonratchathani, Kamphaengphet, Krabi, Surin and Bangkok; regions 
of residence included Ayutthaya, Ratchaburi, Rayong, Prachinburi, 
Uthaithani, Chanthaburi, Loei, Samutprakarn, Samut Sakhon, 
Mahasarakham, Chaiyaphum, Saraburi and Songkhla.
Table 1 
Demographic data, risk exposure and clinical outcome of acute hepatitis E patients classified by patient risk [n(%)]. 
Factor Median age†† Male
Immune-compromise
host
Post transplantation Liver cirrhosis Very elderly
Raw pork
exposure
Admission
rate
Mean admission
duration (d) †††
90 day
mortality
All cases (n=40) 49(27-92) 32(80.0) 7(17.5) 2(5.0) 5(12.5) 5(12.5) 8(20.0) 21(52.5)   20.7依32.1 2(5.0)
High risk group (n=16)† 63(32-92) 11(68.7) 7(43.7)   2(12.5) 5(31.2) 5(31.2) 3(18.7) 10(62.5)   31.8依43.9  2(12.5)
Low risk group (n=24) 47(27-75) 21(87.5) - - - - 5(20.8) 11(45.8) 10.6依9.5   0(0)
P  value 0.13 0.15 0.98 0.30 0.13 0.07
†Risk group defined as patients with one of the following clinical risks: very elderly (>80 years), liver cirrhosis or immune-compromised/post transplantation. 
††Followed by Min-Max. 
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  Overall mortality rate from acute hepatitis E in Thailand 
was 5% (2/40). The 90-day mortality rate in patients at high 
risk was 12.5% (2/16) compared to 0% in the low risk group. 
Two fatal cases from acute hepatitis E were observed in a 
very elderly patient and a cirrhosis patient. Cause of death 
was multi-organ dysfunction related to acute liver failure 
after acute hepatitis E infection.
  In six cases (6/40), the virus could be detected in serum 
or stool by RT-PCR and sequencing. All sequences were 
submitted to the GenBank database under accession 
numbers FJ653660 for complete genome, JX679072-6 for 
ORF1; GU947815 and JX841316 for ORF2. Phylogenetic 
analysis of ORF1 and ORF2 sequences in comparison with 
the known genotypes showed that the viruses were classified 
as HEV genotype 3f, and they were closely related to swine 
HEV strains from Thailand (Figure 2). 
4. Discussion
  This study has reported clinical manifestations of patients 
who were diagnosed with acute sporadic symptomatic HEV 
infection and treated at the tertiary hospital between 2009 
and 2013. These cases originated from various regions of 
Thailand which confirmed the sporadic nature of HEV 
genotype 3. We found that middle-aged and elderly 
individuals were at higher risk of infection, which is 
consistent with a previous report[20], and the majority of 
patients diagnosed with symptomatic acute HEV hepatitis 
were male. Acute HEV infection presented with various 
clinical symptoms, with the most pronounced one being 
jaundice. These can mimic other viral hepatitis and various 
causes of hepatitis including drug induced liver injury[21]. 
None of the HEV patients in this study had a history of 
epidemic jaundice. 
  Acute hepatitis E in Thailand presented with clinical 
symptoms of acute viral hepatitis and tended to be more 
severe in high risk patients including elderly, cirrhotic and 
immune compromised patients. This study established that 
levels of serum alkaline phosphatase at presentation were 
more pronounced in the high risk group. Multiple conditions 
such as pregnancy, alcoholic liver disease and pre-existing 
chronic liver disease were related to high mortality from 
acute HEV infection[22,23]. 
  Extra-hepatic manifestations, such as acute pancreatitis, 
hematological abnormalities, autoimmune phenomena, 
and neurological syndromes have been reported, although 
the pathogenesis of these manifestations has remained 
unclear[24]. One patient from our study developed extra-
hepatic neurological complications of acute hepatitis E[16]. 
Our data have shown that acute HEV infection can have 
various clinical presentations and outcomes. 
  Longer duration of hospitalization was observed in elderly, 
cirrhotic and immune-compromised patients. In this study, 
the 90-day mortality rate in high risk patients was 12.5% 
compared with 0% in the low risk group. Previously reported 
mortality rates in HEV epidemics have ranged from 0.2% 
to 4.0%, potentially increasing to 10%-25% in pregnant 
Table 2 
Clinical presentation of acute hepatitis E patients classified by patient risk [n(%)]. 
Clinical presentation Encephalopathy Icterus Nausea Vomiting Diarrhea Abdominal pain Decolorized stool Dark urine Pruritus Malaise Headache Fever
All cases (n=40) 2(5.0) 32(80.0) 14(35.0) 7(17.5) 8(20.0) 12(30.0) 1(2.5) 25(62.5) 9(22.5) 21(52.5) 1(2.5) 16(40.0)
High risk group (n=16)†   2(12.5) 11(68.8)   6(37.5) 3(18.8) 5(31.3)   3(18.8)         0(0) 10(62.5) 3(18.8)  6(37.5)    0(0)   8(50.0)
Low risk group (n=24)         0(0) 21(87.5)   8(33.3) 4(16.7) 3(12.5)   9(37.5) 1(4.1) 15(62.5) 6(25.0) 15(62.5) 1(4.1)   8(33.3)
P  value 0.07 0.26 0.67 0.79 0.12 0.25 0.42 0.79 0.72 0.17 0.42 0.22
†Risk group defined as patients with one of the following clinical risks: very elderly (>80 years), liver cirrhosis or immune-compromised/post transplantation. 
Table 3
Laboratory data of acute hepatitis E patients classified by patient risk.
Laboratory data TB (mg/dL) DB (mg/dL) AST (U/L) ‡ ALT (U/L) ‡ ALP (U/L) INR Peak TB (mg/dL) ‡ Peak DB (mg/dL) ‡ Peak INR
All cases (n=40) 10.4依9.9 8.5依8.6 226(24-5 440) 463(32-3 986) 192依96 1.25依0.34 10.4(0.7-56.5)   9.2(0.4-37.5) 1.4依0.4
High risk group (n=16) †   9.4依9.5 7.1依7.7  197(117-5 440) 237(54-3 986)   221依119 1.35依0.30 13.1(4.6-56.5) 10.3(2.6-37.5) 1.5依0.6
Low risk group (n=24)   11.1依10.3 9.6依9.2 324(24-3 266) 495(42-3 750) 156依57 1.17依0.30 10.0(0.7-41.0)   7.7(0.4-34.0) 1.2依0.2
P  value 0.62 0.40 0.51§ 0.18§ 0.01* 0.20 0.46§ 0.69§ 0.07
Plus-minus values are mean 依 SD for all comparisons. TB: total bilirubin, DB: direct bilirubin, AST: Aspartate transaminase, ALT: Alanine transaminase, ALP: 
alkaline phosphatase, INR: international normalized ratio. †Risk group defined as patients with one of the following clinical risks: very elderly (>80 years), liver 
cirrhosis or immune-compromised/post transplantation. *Statistically significant, ‡ media (range), § Mann-Whitney U test.
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women[22]. 
  HEV genotype 3 infection has been recognized as zoonotic 
but the definitive primary source of infection has as yet 
proven difficult to discover[25]. Eight of our patients had a 
history of raw pork intake (8/40, 20%). Evidence of pigs as 
a reservoir for human HEV disease has previously been 
reported with up to 21.1% seroprevalence[8]. HEV-RNA was 
detected in six cases from sera or stool. Characterization 
and phylogenetic analysis of ORF1 and ORF2 sequences 
of Thai strains showed that they clustered within HEV 
genotype 3f. One case from our series harbored HEV 
resembling swine HEV that has been previously reported[8]. 
Our HEV sequences exhibited the same genotype (3f) closely 
related to the swine HEV Thailand strains[26]. Infection of 
the Thai population may have originated from raw pork or 
contaminated water and food on pig farms.  
  In conclusion, acute HEV infection in Thailand can be 
found sporadically and has various clinical presentations 
and outcomes. Higher mortality rate and longer duration 
of hospitalization were observed in very elderly, cirrhotic 
and immune-compromised patients. HEV genotype 3f was 
detected in all cases and the infection may have originated 
from swine.
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Figure 2. Phylogenetic tree of the ORF1 (A) and ORF2 (B). 
The samples from this study were indicated at the respective branches. Symbol ▲ strains were isolated from swine; •  strains were isolated from 
human.   
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